Liquid biopsies for early cancer detection: Current and future trends
Wednesday, July 9, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
Early cancer detection remains one of the biggest challenges in oncology, with many cancers going undetected until later stages when treatment options are more limited. Advances in multi-cancer early detection (MCED) aim to address this by identifying multiple cancer types through a single test, often using a simple blood draw.
This has been made possible by the rise of liquid biopsies, which offer a less invasive, faster alternative to traditional tissue biopsies. However, the accuracy and reliability of these tests hinge on one critical factor: sample stability. The choice of blood collection tube plays a vital role in preserving analytes and ensuring high-quality, reproducible results. As the field evolves, combining multiomics with robust pre-analytical practices is key to unlocking the full potential of liquid biopsy technologies.
Join us for this panel discussion – held in partnership with Streck – exploring the future of early cancer detection and the science behind better liquid biopsies. As part of our Accelerating Science feature, this session brings together leading experts to dive deep into the evolving landscape of cancer detection and the pivotal technologies delivering reliable diagnostic outcomes.
Meet our experts:
- Dr. Tina Clarke Dur, Vice President of Epidemiology and Distinguished Scientist at GRAIL
- Dr. Gary Pestano, Chief Development Officer at Biodesix
- Kevin Billings, Director of Business Segment – Stabilization at Streck
Key learning objectives:
- Gain insights into cutting-edge advancements in multicancer early detection assay development, including strategies for improving sensitivity and specificity.
- Understand best practices for assay distribution, with a focus on ensuring accessibility and minimizing logistical challenges.
- Learn pre-analytical techniques to streamline workflows and maximize scalability in multicancer early detection testing.
- Acquire knowledge on how to collaborate effectively with key opinion leaders to drive innovation and optimize implementation of MCED assays.
Whether you're a researcher, clinician or healthcare innovator, this session is your opportunity to hear directly from the pioneers pushing the boundaries of what's possible in cancer detection.
Speakers
Moderator
Featured products
Request Quote for All Products
Nucleic Acid BCT™
StreckNucleic Acid BCT is a direct draw venous whole blood collection device that maintains draw-time concentrations of cell-free DNA, cell-free RNA and extracellular vesicles for up to 7 days when stored at room temperature.? Once isolated from stored plasma, cell-free DNA and cell-free RNA are suitable for many downstream applications. Nucleic Acid BCT is currently available in a 5 mL volume. 10 mL volume is coming soon.
Protein Plus BCT™
StreckProtein Plus BCT is a direct draw whole blood collection tube intended for the stabilization of draw-time concentrations of plasma proteins for up to 5 days* at ambient temperature. *Depending on protein
Cell-Free DNA BCT®
StreckFor In Vitro Diagnostic Use. Cell-Free DNA BCT is a direct-draw venous whole blood collection device intended for the collection, stabilization and transport of venous whole blood samples for use in conjunction with cell-free DNA next generation sequencing assays For that have been cleared or approved for use with samples collected into the Cell-Free DNA BCT device. Performance characteristics of this device have only been established on the Guardant360 CDx assay.
